NCT04080388

How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study)

Hillel Yaffe Medical Center·Phase 3·ClinicalTrials.gov·diagnostic test
View on ClinicalTrials.gov
Study focus
Disease/Condition
Heart Failure Acute
Drug/Device/Intervention
Lung Impedance Device
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Hillel Yaffe Medical Center
Location
Hadera, Israel
Timeline & enrollment
Phase
Phase 3
Start date
Sep 01, 2019
End date
Sep 01, 2021
Enrollment
200 participants
Primary outcome

Prevention of heart failure re-admission,Prevention of heart failure re-admission

Summary

The readmission of Heart Failure (HF) patients for exacerbation HF within 30-day is unmet
 goal. The mail reason for readmission is excessive accumulation of fluid in patient's lung.
 According our data (1,2) around 40% of HF patient have excessive lung fluid at discharge from
 HF hospitalization (unacceptable residual congestion on discharge). In other words, around
 40% patients are discharged from HF hospitalization prematurely when they are not ready to be
 discharged. Only 60% of HF patients are discharged from HF admission with acceptable level
 of residual pulmonary congestion (2). There are some techniques to assess readiness of HF
 patients for discharge. Pulmonary congestion (lung fluid accumulation) may be assessed
 non-invasively by measurement Brain Natriuretic Peptide (BNP), (3,4), by lung ultrasound
 (LUS), (5-7) and by Lung Impedance (LI) method (1,2). LUS is operator depended technique. LI
 and BNP techniques are most reliable methods (2) and easy to use.

ICD-10 classifications
Heart failureHeart failure, unspecifiedCongestive heart failureInjury of heartInjury of heart, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04080388
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04080388 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hillel Yaffe Medical Center and is currently status unknown. The study focuses on Heart Failure Acute. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.